The effects of acetylcholine, ischemia, and anoxia on myocardial cyclic GMP and cyclic AMP were investigated in isolated rat hearts perfused under either constant flow (14 ml/min) or constant pressure (100 cm H,O) conditions with physiological saline gassed with 95% O,-5% COj. In paced, constant flow-perfused hearts, cyclic GMP increased from a control of 35 to 62 fmol/mg protein and remained elevated, while dP/dt, an index of contractility, decreased only transiently from 2,650 to 1,750 mm Hg/sec then returned toward control levels during the first 2 minutes of 1 pM acetylcholine. In paced, constant pressure-perfused hearts, the acetylcholine caused a persistent decrease in dP/dt and a transient increase in coronary perfusate flow, followed by a marked decrease in flow. Reduction of coronary perfusion to one-half control flow and ischemia (termination of perfusion) increased cyclic GMP from 43 to 85 and 127 fmol/mg protein, respectively. Anoxia (perfusion with physiological saline gassed with 95% Nj-5% COi) did not produce a significant change in cyclic GMP. Neither atropine nor Indomethacln at 10 fiM prevented the increase in cyclic GMP produced by ischemia, but the musearinic blocking agent did block the increase caused by acetylcholine. Cyclic AMP increased from a control of 3.8 to 6.0 pmol/mg protein with anoxia and to 12.8 pmol/mg protein with 1 /iM isoproterenol, but was not affected by acetylcholine or ischemia. Myocardial lactate increased significantly only with ischemia. Ca-free perfusion for 1 minute partially blocked the increase in cyclic GMP caused by ischemia, but did not prevent the acetylcholine-induced increase in the cyclic nucleotide. These results indicate: (1) that there is not always an inverse relationship between myocardial cyclic GMP and contractility and (2) that limitation of coronary perfusion augments cardiac cyclic GMP by a mechanism^) that is independent of acetylcholine but largely dependent on external Ca l+ . Ore Res 49: 912-932, 1981 
THE cyclic nucleotides, adenosine 3',5'-monophosphate (cAMP) and guanosine 3',5'-monophosphate (cGMP) are implicated as playing important roles in the biological actions of /?-adrenergic and cholinergic agents in the mammalian heart (George et al, 1970 (George et al, , 1973 Dobson et al., 1976; Nawrath, 1976; Dobson, 1978) . cAMP seems to be important in the /?-adrenergic catecholamine-induced increase in contractility and glycogen phosphorylase activity Dobson, 1978) . cGMP may play a role in the cholinergic-induced decrease in cardiac contractility (George et aL, 1970 (George et aL, , 1973 Nawrath, 1976) . cGMP is also suspected to be involved in the acetylcholine-produced attenuation of the catecholamine-elicited increase in contractility and phosphorylase activity (Watanabe and Besch, 1975; Gardner and Allen, 1976 ). The enzymes responsible for cyclic nucleotide synthesis, namely adenylate cyclase and guanylate cyclase, are present in the mammalian myocardium (Drummond and Duncan, 1970; Limbird and Lefkowitz, 1975) .
Acetylcholine has been shown to produce a rapid concentration-dependent increase in cGMP concentration in the isolated rat heart that correlates with the magnitude of the cholinergic-elicited decrease in myocardial contractility (George et al., 1970 (George et al., , 1973 . However, it has been reported that low concentrations of acetylcholine and carbamylcholine (carbachol) depress contractility in isolated atrial preparations without producing a detectable increase in cGMP (Brooker, 1977; Diamond et al., 1977) . Acetylcholine has also been reported to increase cGMP in the isolated guinea pig heart without significantly affecting contractility (Watanabe and Besch, 1975) . Other studies suggest that the increase in cGMP elicited by agents other than acetylcholine do not correlate with changes in contractility. For example, sodium nitroprusside and sodium azide have been shown to increase cardiac cGMP without affecting contractility (Diamond et al, 1977; Katsuki et al., 1977) .
Whereas a great deal of information is available regarding the effect of cholinergic agents on myocardial cGMP, much less is known about the effect of ischemia and anoxia on cardiac purine cyclic nucleotides. In dogs, chronic coronary ligation (3-35 days) has been reported to produce an increase in cGMP and a decrease in cAMP in the myocardium that was previously perfused by the ligated arteries (Stewart et al., 1978) . Acute ischemia in the in vivo rat heart has been shown to produce an increase in cAMP within seconds (Dobson and Mayer, 1973) . Hypoxic perfusion of isolated rat hearts (12% O 2 -84% N 2 -4% CO 2 ) resulted in an increase in cAMP and a decrease in myocardial cGMP (Nesher et al, 1977) . Anoxic perfusion (95% N 2 -5% CO 2 ) of isolated rat hearts has been reported to cause a sustained increase in myocardial cGMP and only a transient increase in cAMP (Busuttil et al., 1976; Busuttil et al., 1978) . Thus, the above reports might suggest that the effects of ischemia and anoxia on myocardial cyclic nucleotides are unresolved. However, the depressant effects of ischemia and anoxia on cardiac contractility are well recognized (Dobson and Mayer, 1973; Rovetto et al., 1973) .
The purpose of this investigation was to study the relationship between myocardial cGMP concentration, contractility, and coronary flow in the myocardium of isolated hearts subjected to either constant pressure or constant flow perfusion and cholinergic stimulation. In addition, the effect of ischemia and anoxia on cardiac cGMP and cAMP was studied and the importance of Ca 2+ in cyclic nucleotide formation investigated.
Methods

Heart Preparation
The isolated perfused rat heart preparation used in these studies was similar to one described previously (Dobson et aL, 1974) . Male Sprague-Dawley rats (250-350 g) were maintained on nonmedicated Purina rat chow ad libitum in rooms with a lighting sequence of 12 hours light and 12 hours dark. The rats were anesthetized with 40 mg/kg sodium pentobarbital (ip) and received 500 U of sodium heparin (ip). After 30-40 minutes, hearts were excised and their aortas immediately slipped onto perfusion cannulas which dripped oxygenated physiological saline solution (PSS) at 7 ml/min. Either constant pressure (100 cm H2O) or constant flow (14 ml/min, unless otherwise indicated, via a Harvard peristaltic pump, frequency of 24/min) retrograde perfusion down the aorta was initiated as soon as each heart was secured. The right atrium was removed and platinum electrodes were placed on the base of the right ventricle in the vicinity of the His bundle so that the heart could be paced at 300 contractions/ min with a minimal voltage and pulse duration (1-2 V, 3-5 msec) supplied by a Grass SD9 stimulator. A degassed saline-filled cannula (polyethylene, 1.5 mm i.d., 8.0 cm long) attached to a Statham straingauge manometer (P23 Dd) was inserted into the chamber of the left ventricle through the left atrium and mitral valve for recording changes in intraven-tricular pressure. Maximum developed intraventricular pressure generally ranged from 85 to 125 mm Hg. In some experiments, a fluid-filled latex balloon was attached to the end of the cannula which permitted the myocardium to develop force at a constant ventricular volume. The intraventricular balloon was initially inflated with fluid until left ventricular pressure development was maximal. The balloon volume was held constant during the course of an experiment. The rate of left ventricular pressure development (dP/dt) was derived from the left ventricular pressure signal by resistance-capacitance differentiation (Hewlett-Packard derivative preamplifier, model 8814A). All pressure and dP/dt data were recorded with a multichannel polygraph (Hewlett-Packard series 7700 recorder).
The hearts were equilibrated for 30 minutes and always perfused with nonrecirculated PSS, pH 7.4 at 37°C. The PSS was prepared fresh daily and contained in millimoles per liter NaCl, 118.4; KC1, 4.69; CaCl 2 , 2.52; NaHCOs, 25.0; MgSO 4 , 1.18; KH 2 PO 4 , 1.18; and glucose 10. For some experiments, calcium-free PSS was prepared by replacing the Ca 2+ with Na 2+ . After the equilibration period, acetylcholine, carbachol (carbamylcholine chloride), or isoproterenol was administered (0.2-0.5 ml/min) into the aortic perfusion cannula just above the heart via a syringe infusion pump (Harvard, model 940) . The resulting perfusion cannula PSS concentration of all agents is that reported herein. Atropine sulfate, propranolol, or phentolamine was delivered to some hearts by the same means of administration 5 minutes prior to and during infusion of either acetylcholine or isoproterenol. Coronary flow was measured in constant pressure-perfused hearts by collecting the venous effluent in a graduated cylinder. In some instances, coronary perfusate was collected every 10 seconds into preweighed 20-ml glass scintillation vials. The flow was determined by weight difference assuming 1 g equivalent to 1 ml of fluid. Myocardial ischemia was produced by termination of perfusion flow. Anoxia wets produced by perfusing the hearts with PSS gassed with 95% N^-5% CO2. After the introduction of one of the above experimental interventions, the hearts were frozen while still attached to the aortic cannula by compression into thin wafers (thickness 1-2 mm) with polished clamps precooled in liquid nitrogen.
Analytical Procedures
Tissue Preparation and Extraction.
Frozen PSS and nonventricular tissue were chipped from the frozen myocardial wafers and the tissue was finely powdered in a liquid nitrogen cooled blender as described previously (Dobson, 1978) . The powdered samples were transferred to screw cap glass vials and stored (2-30 days) at -80° C. Extraction procedures were initiated by weighing out portions of each sample at -25°C. VOL. 49, No. 4, OCTOBER 1981 For cGMP assays, approximately 300 mg of muscle were transferred to a Duall homogenization tube (glass-glass, size 22, Kontes Glass Co.) Based on sample weight, 5 volumes of ice-cold 0.4 M trichloroacetic acid were added and the mixture was homogenized at 0°C. The homogenate was centrifuged at 2,000 g for 30 minutes at 0°C and the supernatant fluid extracted 5 times with 4 volumes of H 2 Osaturated ethyl ether. The extract was subject to reduced atmospheric pressure (328 mm Hg) at 37°C for 30 seconds to remove most of the remaining ether. The extract was then placed on 0.5 X 5 cm alumina (1 g of aluminum oxide, Woelm neutral, activity grade 1) column previously equilibrated with 0.06 M Tris, pH 7.5, to remove most of the noncyclic purine nucleotides (Mao and Guidotti, 1974) . The alumina column was first eluted with 10 ml of the above Tris buffer, then with 5 ml of 0.6 M Tris, pH 7.5. Both elutions were collected directly onto a 0.5 X 3.5 cm Bio Rad AG 1-X8 (200-400 mesh, chloride form) column washed previously with 15 volumes of H 2 O. The latter column was eluted with 10 ml of 0.02 N HC1, and this eluate, which contained most of the cAMP, was discarded. A second elution with 10 ml of 2 N HC1 was collected, lyophilized, and contained primarily cGMP. The column chromatographic procedure was effective in removing the non-cyclic purine nucleotides as judged by chromatographing some samples on thin layer polyethyleneimine cellulose sheets (Trifilo and Dobson, 1976 ) and comparing them to samples not subjected to the column chromatography. The sample was resuspended in 100 /A of 0.05 M sodium acetate buffer, pH 6.2, and assayed for cGMP. Prior to homogenization of the tissue, tracer amounts of tritiated cGMP (approximately 4,200 dpm or 50 fmol) were added to the powdered hearts to check for recoveries. A portion of the resuspended cGMP sample (after lyophilization) was counted to allow for determination of recoveries which ranged from 40 to 50%. The values reported for cGMP have been corrected for recoveries.
For cAMP, another 35-to 40-mg portion of the powdered muscle was transferred to a Duall homogenizing tube (size 20), 0.5 ml of ice cold 0.6 M trichloroacetic acid added and the tissue plus acid immediately homogenized at 0°C. The homogenate was centrifuged at 3,000 g for 20 minutes at 0°C and the supernatant fluid was extracted 5 times with 4 volumes of H2O-saturated ethyl ether. A second portion of the homogenous powder of every third or fourth sample was routinely weighed out and 20 pmol of cAMP were added to determine the loss of cAMP that occurred during the extraction procedure. Recovery ranged from 78.7 to 80.1% and the values reported for cAMP have been corrected for the consistent recoveries.
For lactate, a third 20-to 25-mg portion of the powdered muscle was transferred to size 20 Duall homogenization tube. Based on sample weight, 5 volumes of ice cold 3 N HC1O* were added and the sample plus acid immediately homogenized at 0°C. The homogenate was centrifuged at 5,000 g for 20 minutes and the resulting supernatant was brought to pH 8-9 with 3.2 M KHC0 3 . After most of the evolved CO 2 had dissipated, the KC1O< precipitate was removed by centrifugation and the extract sissay ed for lactate.
Chemical Assays
The concentration of cGMP was measured in the chromatographed tissue extracts by radioimmunoassay basically after the methods of Steiner et al. (1972) . The assay reaction mixture contained 0.05 M sodium acetate buffer, pH 6.2, cGMP antiserum, I2S I-succinyl cGMP ( 125 I-Sc-cGMP), and either known amounts of unlabeled cGMP (standards) or tissue extracts in a final volume of 125 /xl. The concentration of cGMP antiserum and 1M I-Sc-cGMP were adjusted so that the total 125 I-Sc-cGMP bound (BT) in the absence of any unlabeled cGMP was 40-45%. The reaction was allowed to incubate for 2.5 hours at 4°C. A second antibody (sheep antirabbit serum) plus diluted (1:200) normal rabbit serum as a carrier protein was added for 16-20 hours at O°C to precipitate the cGMP antiserum-125 I-Sc-cGMP complex. One ml of 0.05 M sodium acetate buffer was added and the precipitate pelleted by centrifugation (2,000 g for 40 minutes, O°C). The supernatant was decanted and 126 I-Sc-cGMP in the pellet quantified in a y counter (Searle model 1195). The limit of sensitivity of the assay was 0.02 pmol/assay tube. Fifty percent displacement of BT occurred upon the addition of 0.4 pmol of cGMP per tube. The possibility of other purines cross-reacting in this assay was unlikely because the concentration of contaminating purines necessary to cause a detectable decrease in BT in the assay was 10 2 -to I0 3 -fold greater (2.5 nmol of either cAMP or guanosine monophosphate, 250 nmol of either guanosine triphosphate or guanosine, and 500 nmol of either adenosine triphosphate or adenosine) than that present in the partially purified extracts. All assays were performed in duplicate and the error between duplicates was generally <1.5%. When the same sample was assayed at different dilutions or in different assays performed on separate days, the agreement was >:96%. The addition of 0.1 mg (0.025 U) phosphodiesterase to tissue extracts before column chromatography removed 98% of the assayable cGMP. The concentration of cGMP is expressed as fmol/mg protein.
The concentration of cAMP was measured in tissue extracts by methods described previously based on the activation of skeletal muscle cAMP-dependent protein kinase. Both in isolated and intact heart preparations of different species, this cAMP assay has been reported to give consistent results (Dobson and Mayer, 1973; Dobson et al., 1976; Dobson, 1978) . The concentration of cAMP is expressed as pmol/ mg protein. The lactate concentration in tissue extracts was determined enzymatically by the method of Passonneau (1974) . The concentration of lactate is expressed as nmol/mg tissue wet weight. Protein was measured by the method of Lowry et al. (1951) , and bovine serum albumin was used as a standard. The protein content of the hearts ranged from 8.82 to 9.98 mg protein/100 mg tissue wet weight.
Materials
Acetylcholine chloride, carbachol (carbamylcholine chloride), /-isoproterenol chloride, atropine sulfate, dl-propranolol, 2-amino-2-methyl-l-propranol, and beef heart lactate dehydrogenase were purchased from Sigma Chemical Co. Phentolamine (Regitine-HCl) was generously supplied by Ciba-Geigy Corp. All salts, acids, solvents, hydrazine hydrate and sodium heparin were certified grade from Fisher Scientific Co. Cyclic and non-cyclic purine nucleotides, nucleosides, nicotinamide-adenine dinucleotide, /-lactate, beef heart phosphodiesterase, and enzymes used for [y-^PJATP synthesis (Glynn and Chappell, 1964 , a substrate for cAMP assay) were from Boehringer Mannheim Corporation. Crystallized bovine albumin was obtained from Pentex Biochemicals. Woelm neutral aluminum oxide was obtained from ICN Pharmaceuticals, Inc. Carrier-free ( 32 P) inorganic phosphate was purchased from New England Nuclear. H-cAMP (specific activity 19 Ci/mmol) was from Amersham-Searle. 125 I-Sc-cGMP (specific activity of approximately 600 Ci/mmol), rabbit cyclic GRIP antiserum, sheep anti-rabbit serum, and normal rabbit serum were obtained from Collaborative Research.
Statistical Methods
An analysis of variance was performed for paired and unpaired observations (Sokal and Rohlf, 1969) . A probability of <0.05 was accepted as indicating a significant difference.
Results
Acetylcholine, cGMP, and Contractility
Acetylcholine produced an increase in myocardial cGMP concentration that was not always associated with a decrease in the rate of left ventricular pressure development.
Constant Flow Perfusion
Acetylcholine infusion for 1 minute produced a dose-dependent increase in myocardial cGMP (Fig.  1) . cGMP increased from a control of 40.1 ± 2.9 to 55.6 ± 2.7 fmol/mg protein with 0.1 fiM acetylcholine. The increase in cGMP produced by acetylcholine was essentially the same whether hearts were paced (300/min) or unpaced. When compared to acetylcholine, carbachol was equipotent and equiefficacious as judged from a dose-response relationship obtained for this compound (data not shown).
The rate of left ventricular pressure development The effect of acetylcholine on myocardial cGMP concentration and contractility in isolated rat hearts perfused at 14 ml/min with oxygenated (95% Oi-5% CO 2 ) PSS and paced (300/min). Acetylcholine was infused directly into the PSS entering the aortas, and the resulting concentrations to which the hearts were exposed for 1 minute are indicated. (dP/dt, an index of contractility) decreased from a control of 2,670 ± 60 to 2,100 ± 100 and 1,610 ± 110 mm Hg/sec after 1 minute of 0.1 and 1 fiM acetylcholine perfusion, respectively, in paced hearts (Fig.  1) . In paced and unpaced hearts, the decreases in dP/dt caused by 1 minute of either 0.01, 0.1, or 1 /IM acetylcholine were similar in magnitude ( Fig. 2) . After 2 minutes of acetylcholine, the dP/dt declined further in unpaced hearts but returned toward control levels in paced hearts. In the paced hearts, the return of dP/dt toward control persisted for an additional 8 minutes of the acetylcholine infusion.
In the unpaced hearts the rate of contraction decreased from a control of 270 ± 11 to 128 ± 12, 90 ± 10, 60 ± 13, and 18 ± 10 contractions per minute with 0.3, 0.5, 1, and 2 minutes, respectively, of 1 fiM acetylcholine. Propranolol, a /9-adrenergic blocking agent, at 10 JIM did not prevent the restoration of contractility observed in paced hearts in which acetylcholine produced only a transient decrease in dP/dt. This concentration of propranolol prevented a 2-to 3-fold increase in dP/dt produced by 0.2-1 HM isoproterenol. Atropine, a muscarinic blocking agent, at 10 UM prevented the decrease in dP/dt and contraction frequency elicited by acetylcholine. Propranolol or atropine alone decreased dP/dt by 0-10% and 1-4%, respectively. During the 2-minutes infusion period, acetylcholine was without affect on VOL. 49, No. 4, OCTOBER 1981 onary flow that occurred during the course of the experiment. Since the protein contents of constant pressure-and constant flow-perfused hearts were 9.69 ± 0.29 and 9.46 ± 0.28 mg/100 mg heart (wet weight), respectively, the constant flow-perfused hearts were not significantly more edematous than the constant pressure-perfused hearts. In both the constant pressure-and constant flow-perfused hearts, the cGMP concentration remained elevated with the continual infusion of acetylcholine for 10 minutes.
The rate of left ventricular pressure development in paced constant pressure-perfused hearts decreased and remained depressed during a 10-minute acetylcholine infusion period in a manner similar to that observed in unpaced constant flow-perfused hearts (Fig. 2) . This contractile response was observed when either a left ventricular pressure cannula or balloon cannula was used to obtain dP/dt.
In the paced constant pressure-perfused hearts, acetylcholine infusion (1 / LCM initially) caused a transient increase (not due to the infusion pump) in coronary perfusate flow from 6.8 ± 0.2 to 8.2 ± 0.3 ml/min within the first 10 seconds of the infusion followed immediately by a pronounced decrease in coronary flow (Fig. 3) . After 30 seconds of the acetylcholine infusion (1 jtM initially), the coronary flow decreased to 3.1 ± 0.4 ml/min. Since coronary left ventricular end-diastolic pressure in paced hearts. However, in unpaced hearts, the cholinergic agent caused a 2-4 mm Hg increase in left ventricular end-diastolic pressure. In experiments in which a fluid-filled balloon cannula was used to hold left ventricular volume constant, acetylcholine produced decreases in dP/dt that were similar to data presented in Figures 1 and 2 for paced and unpaced hearts.
Constant Pressure vs. Constant Flow Perfusion
Since previous reports (George et al., 1970 (George et al., , 1973 Watanabe and Besch, 1975) have suggested various relationships between cGMP and contractile state with acetylcholine perfusion in constant flow-and constant pressure-perfused hearts, it was important to compare these perfusion situations. When paced hearts, were used, a submaximal concentration of acetylcholine was employed to maximize any differences that might occur. Infusion of acetylcholine initially at 1 fiM produced within 1 minute a 3.5-fold increase in myocardial cGMP in constant pressure-(100 cm H 2 O) perfused hearts compared to only a 1.7-fold increase in the cyclic nucleotide in constant flow-perfused hearts (Fig. 3) . It should be noted that the concentration of acetylcholine delivered to the myocardium of the constant flow-perfused hearts remained constant at 1 /IM, whereas in the constant pressure-perfused hearts the concentration of acetylcholine delivered to the myocardium varied and was inversely related to changes in cor- The effect of 1 /IM acetylcholine on the formation of myocardial cGMP m rat heart? perfused under either constant pressure or constant flow conditions. All hearts were paced. Continuous acetylcholine infusion was initiated at zero time and carried out for the times indicated as outlined in Figure 1 . Coronary flow of the constant pressure-perfused hearts was determined at the times indicated as described in Methods. While the concentration of acetylcholine was initially 1 fiM in the constant pressure-perfused hearts the concentration to which the myocardium was actually exposed varied after zero time inversely with coronary flow Values represent the mean of four experiments. See the legend of Figure 1 for further explanation. The effect of coronary flow on myocardial cGMP in perfused rat hearts. Hearts were paced and perfused for 30 minutes at 14 ml/min with oxygenated (95% Ch-5% CO,) PSS, then at the flow indicated for 10 minutes. cGMP was determined in the myocardium of frozen hearts. Values represent the mean of six experiments. Asterisks denote a significant difference from a coronary flow value of 14 ml/min. See the legend of Figure 1 for further explanation.
flow decreased to 2.5 ± 0.4 ml/min after 60 seconds of the acetylcholine infusion, the actual concentration to which the heart was exposed probably approached 3 JIM. Atropine (10 JIM) prevented both the initial increase and the latter decrease in coronary flow caused by acetylcholine. Perfusion of hearts with 10-50 /IM phentolamine, an a-adrenergic blocking agent, reduced the acetylcholine-induced decrease in coronary flow by 77%. Propranolol (10 JUM) had no affect on the decrease in coronary flow caused by acetylcholine. Atropine, phentolamine, or propranolol alone reduced coronary flow by 1-2, 6-10, and 4-8%, respectively.
Ischemia, Anoxia, and cGMP
Since coronary flow decreased in constant pressure-perfused hearts during acetylcholine infusion, it seemed possible that, besides the enhanced concentration of acetylcholine delivered to the myocardium, coronary flow might be an additional determinant of myocardial cGMP concentration. To determine whether coronary perfusate flow itself was important, paced hearts initially equilibrated at a perfusion rate of 14 ml/min for 30 min, were then subjected to perfusion flows of either 0, 7, 14, or 30 ml/min for 10 minutes. Reduction of coronary perfusion from 14 to 7 and 0 (ischemia) ml/min produced a significant increase in myocardial cGMP from 43 to 85 and 127 fmol/mg protein, respectively, whereas no change in the concentration of the cyclic nucleotide resulted from an increase in flow to 30 ml/min (Fig. 4) . Upon initiation of myocardial ischemia by termination of coronary perfusion (zero flow), the elevation of cGMP became significant within 2 minutes and maximal after 10 minutes (Fig. 5 ). Within the first 4 minutes of ischemia, cGMP increased more than 2-fold from 38 to 90 fmol/mg protein.
Since ischemia produced a marked increase in myocardial cGMP, paced hearts were made anoxic for 10 minutes by perfusing the hearts at 14 ml/min with PSS gassed with 95% N 2 -5% CO 2 to determine whether a lack of O2 delivery would cause an elevation in cGMP. Anoxia, unlike ischemia and acetylcholine, did not affect myocardial cGMP (Fig. 6) . The myocardial cGMP concentration determined after 0.5, 1, 2, and 4 minutes of anoxia was also not significantly different from the value in oxygenated myocardium (PSS at 14 ml/min, gassed with 95% O 2 -5% CO 2 ). The concentration of myocardial lactate in control, acetylcholine stimulated (1 JIM, 1 minute, constant flow perfused) ischemic (10 minutes) and anoxic (10 minutes) hearts was 1.67 ± 0.13, 1.44 ± 0.18, 4.90 ± 0.24 (significantly different from control), and 1.74 ± 0.16 nmol/mg tissue (weight wet), respectively.
Continual infusion of atropine (10 /XM) for 5 minutes before the paced hearts were either subjected to 10 /iM acetylcholine or rendered ischemic prevented the acetylcholine-produced increase in cGMP but did not appreciably attenuate the increase in cGMP caused by ischemia (Fig. 7) . The atropine also did not affect the early increase in cGMP that occurred after 2 minutes of ischemia. Indomethacin at 10 JIIM in the perfusion PSS did not The effect of acetylcholine, ischemia, and anoxia on myocardial cyclic cGMP and cAMP. Isolated rat hearts were placed and perfused at 14 ml/min for 30 minutes with oxygenated (95% Ch-5% CCh) PSS. Acetylcholine was infused into the oxygenated PSS resulting in a concentration of 1 JJM for 1 minute. Ischemia was introduced for 10 min by termination of heart perfusion. Anoxia was introduced for 10 minutes by substitution of 95% Ch-5% CO 2 with 95% N 2 -5% CCh. All hearts were frozen for the determination of cGMP and cAMP. Values represent the mean of six to nine experiments. Asterisks denote a significant difference from the appropriate control value. See the legend of Figure 1 for further explanation.
influence the ischemia-induced increase in myocardial cGMP.
cGMP, cAMP, Ischemia, Anoxia, and Calcium
Myocardial cAMP increased significantly from 3.8 ± 0.5 to 6.0 ± 0.4 pmol/mg protein in paced anoxic hearts but did not differ from control in paced ischemic or acetylcholine (1 JUM) -stimulated hearts (Fig. 6 ). Isoproterenol (1 JM) infusion for 1 minute significantly increased cAMP from a control of 3.8 ± 0.8 to 12.8 ± 1.2 pmol/mg protein in paced constant flow-perfused hearts. The isoproterenol did not influence the cGMP concentration in these hearts.
Since Ca 2+ appears to play an important role in tissue cGMP metabolism (Schultz et al., 1973) , the effect of this cation on the acetylcholine and ischemia elicited increase in cGMP was determined. Constant flow perfusion of paced hearts with Ca z+free PSS for 1 minute before the termination of coronary flow decreased the ischemia-induced increase in cGMP but did not affect the increase in the cyclic nucleotide caused by 1 UM acetylcholine (Fig. 8) . Upon the initiation of Ca + -free perfusion, the hearts ceased contracting within 15 seconds. Perfusion of hearts with Ca 2+ -free PSS for 20 minutes prevented the acetylcholine-elicited increase in myocardial cGMP. Twenty minutes of Ca 2+ -free perfusion prior to the initiation of ischemia atten- The effect of atropine on the acetylcholineand ischemia-induced increase in myocardial cGMP. Rat hearts were perfused for 30 minutes as described in the legend of Figure 6 with (c) or without (s) 10 /±M atropine sulfate for the last 5 minutes. Then either 10 jiM acetylcholine was administered or ischemia was introduced, as described in the legend of Figure 6 . Values represent the mean of six experiments. Asterisks denote a significant difference from the appropriate control value. See the legend of Figure 1 for further Control Acetylcholine Ischemio
FIGURE 8
The effect of calcium on the acetylcholine and ischemia-induced increase in myocardial cGMP. Rat hearts were perfused with or without calcium (2.52 mM) added to the oxygenated PSS, as described in the legend of Figure 6 . Acetylcholine (1 fiM) was infused for 1 minute and ischemia was induced for 10 minutes, as described in the legend of Figure 6 . In the absence of Ca 1+ , the acetylcholine was administered or the ischemia induced after either 1 or 20 minutes of exposure of hearts to Ca-free oxygenated PSS. Values represent the mean of five experiments. Asterisks denote a significant difference from the appropriate control value. Daggers represent a significant difference from the value in the presence of calcium. See the legend of Figure 1 for further explanation.
uated but did not completely prevent the ischemiaproduced increase in cGMP.
Discussion
Acetylcholine, cGMP, and Contractility
Constant Flow Perfusion
Acetylcholine administration to isolated constant flow-perfused hearts, either paced or unpaced, produced a dose-dependent increase in myocardial cGMP concentration. Carbachol, a choline ester resistant to hydrolysis, produced similar dose-response results indicating that the acetylcholine probably did not undergo significant destruction when freshly prepared and infused into the aortic cannula of perfused hearts. There was a correlation between the increase in myocardial cGMP and the decrease in contractility (dP/dt) after acetylcholine administration for 1 minute in paced and unpaced hearts ( Figs. 1 and 2) . These results are in agreement with similar studies performed by George et al (1970 George et al ( , 1973 . However, in paced hearts, acetylcholine caused only a transient dose-dependent decrease in dP/dt during the first 2 minutes of infusion (Fig. 2) while the myocardial GMP concentration remained elevated (Fig. 3) . Thus, there was not always an inverse relationship between cGMP concentration and contractility. Alterations in left ventricular chamber volume probably are not involved, since left ventricular end-diastolic pressure did not change with acetylcholine infusion in paced hearts. The return of contractility toward control following the transient decrease probably was not due to an acetylcholine-induced release of catecholamines (Haeusler et al., 1968) because propranolol, at a concentration that prevented the positive inotropic response of isoproterenol, did not prevent the restoration of contractility toward control levels. Therefore, the rapid and transient decrease in contractility observed with acetylcholine stimulation in paced hearts may indicate: (1) that the decrease in contractility is not related to an increase in myocardial cyclic GMP or (2) that if there is an inverse relationship between cGMP and contractility, the prolonged effect of the cyclic nucleotide is masked by a compensatory mechanism.
Other investigators also have reported a lack of association between an increase in cGMP and a decrease in contractility (Watanabe and Besch, 1975; Brooker, 1977; Diamond et al., 1977) . Using paced isolated perfused guinea pig hearts, Watanabe and Besch (1975) reported that a 2-minute infusion of acetylcholine produced a dose-dependent increase in cGMP but had only a slight negative inotropic effect that did not show a marked concentration dependence. In isolated guinea pig and eit atrial preparations, Brooker (1977) and Diamond et al. (1977) , respectively, have shown that low concentrations of acetylcholine attenuate atrial twitch tension without causing a detectable increase in cGMP. However, the disagreement between experimental results may be due to differences in species used or differences in experimental techniques employed. The effects of acetylcholine may be mediated in part by changes in the intracellular concentrations of cGMP. However, it is possible that the acetylcholine-induced reduction of the slow inward Ca 2+ current (Ten Eick et al., 1976) may represent another pathway independent of cGMP that is important in the manifestation of the effects of this choline ester.
Constant Pressure vs. Constant Flow Perfusion
Acetylcholine produced approximately a 2-fold greater increase in myocardial cGMP in constant pressure-perfused hearts as compared to hearts perfused with constant flow (Fig. 3) . In the constant pressure-perfused hearts, an increase in coronary flow occurred within the first 10 seconds of acetylcholine infusion, which was expected (Folkow et al., 1949) . However, after the initial increase, coronary flow precipitously decreased over the next 10-30 seconds and remained at approximately one-third the control level (Fig. 3) . It is likely that an acetylcholine-elicited release of catecholamines could have played an important role in the decrease in coronary flow, since phentolamine, an a-adrenergic blocking agent, substantially attenuated the coronary flow reduction. The catecholamine release presumably was small in magnitude, localized in the vicinity of the coronary resistance vessels, and mediated by a a-adrenergic vasoconstriction, since total myocardial cAMP concentration was not significantly influenced with acetylcholine administration (Fig. 6 ). The decrease in coronary flow may have also been associated with a decrease in myocardial oxygen consumption (Eckenhoff et aL, 1947) fostered by the acetylcholine-induced decrease in contractility. A direct vasoconstricting effect of acetylcholine on the coronary vessels (De La Lande et al., 1974) also could have contributed to the decrease in coronary flow. Thus, the decrease in coronary flow observed could have caused a partial degree of ischemia which, in turn, could have been a factor contributing to the marked cGMP elevation in constant pressure-perfused hearts. Since acetylcholine was delivered into the aortic cannula so as to achieve a desired concentration based on the control coronary flow rate with a constant flow infusion pump, a reduction in coronary flow elicited by acetylcholine would only increase the effective concentration of the agent administered. Presumably, this was another factor responsible for producing what appeared to be an enhanced increase in myocardial cGMP at a given concentration of acetylcholine in the constant pressure-perfused hearts. This suggests that there may be problems inherent in studies such as the one reported here and others (George et al., 1973) in which acetylcholine infusions into constant pressure-perfused VOL. 49, No. 4, OCTOBER 1981 hearts have been used to investigate the relationship between myocardial cGMP and contractility with acetylcholine stimulation.
Myocardial cGMP Values
The values for myocardial cGMP concentration reported here are approximately one-tenth those reported by Busuttil et al. (1978) , George et al. (1970 George et al. ( , 1973 , and Keely et aL (1977) and one-third those reported by Watanabe and Besch (1975) . The reason for the discrepancy is not readily apparent, but the column chromatographic steps to which the tissue extracts were subjected and the high specificity of the cGMP antiserum used in the present study, as well as species and/or other differences in experimental technique, may be responsible.
Ischemia, Anoxia, and cGMP
Reduction of coronary flow in paced constant flow-perfused hearts to levels below 14 ml/min produced an increase in myocardial cGMP (Figs. 4 and 5) . Anoxia (perfusion with PSS gassed with 95% N2-5% CO2) was also employed to limit O2 delivery to the myocardium. However, this intervention was without effect on cGMP (Fig. 6) . Therefore, the ischemia-elicited increase in cardiac cGMP is probably not due to a reduction in myocardial oxygen tension per se. These results are in agreement with the ischemic dog myocardial studies of Steward et al. (1978) , but do not agree with the anoxic rat heart studies of Busutill et al. (1978 Busutill et al. ( , 1976 . The latter reported that isolated rat hearts perfused with a modified Tyrode's solution (containing 5 mM Ca 2+ and 5 mM glucose) gassed with 95% N2-5% CO 2 increased myocardial cGMP approximately 1.6-fold with 1-5 minutes of anoxic perfusion. These results are not directly comparable to those of the present study because the hearts were perfused at constant pressure. Thus, it is possible that coronary flow may have been limiting in their experiments and this in turn could have contributed to the observed increase in cGMP.
It is well known that the effects of ischemia and anoxia on cardiac metabolism are different (Dobson and Mayer, 1973; Rovetto et al., 1973) . In the present studies, the concentration of myocardial lactate markedly increased in the ischemic hearts as compared to the anoxic hearts where flow was not limited. Presumably, the lactate formed in the anoxic hearts was continually released and washed into the coronary perfusate. The washout of metabolites, lactate being a good example (Rovetto et al., 1973) , may also partially explain why cGMP did not accumulate in the anoxic hearts as it did in the ischemic hearts. Anoxic hearts were continually perfused with PSS containing glucose, whereas the ischemic hearts were not perfused. Consequently, the ischemic hearts were not continuously supplied with exogenous glucose. Recently, Busuttil et al. (1976) reported that in oxygenated isolated hearts, the absence of exogenous glucose was associated with an elevation of myocardial cGMP. Therefore, the availability of exogenous oxidizable substrates may be another important determinant of cGMP formation.
Atropine completely blocked an acetylcholineinduced increase in cGMP that was similar in magnitude to the increase in the cyclic nucleotide produced by ischemia. However, atropine did not prevent the ischemia-elicited increase in cGMP (Fig.  7) . This indicates that the ischemia-elicited increase in cGMP was probably not due to the release of myocardial acetylcholine. It has been reported that the release of prostaglandins from the heart is enhanced following either myocardial ischemia or anoxia (Block et al., 1974; Berger et al., 1976) and that prostaglandins are capable of facilitating cGMP formation (Kadowitz et al., 1975) . However, indomethacin, an inhibitor of prostaglandin synthesis, did not prevent the increase in myocardial cGMP elicited by ischemia, suggesting that the prostaglandins were not involved in the present study. In addition, ATP has been shown to inhibit both a soluble and particulate guanylate cyclase in a cellfree preparation from rat heart (Limbird and Lefkowitz, 1975) . It is feasible that the marked decrease in ATP that occurs with myocardial ischemia (Imai et al., 1964) may relieve the inhibitory effect of ATP on guanylate cyclase and thereby promote cGMP synthesis. cGMP, cAMP, Ischemia, Anoxia, and Calcium Anoxia elicited a slight increase in myocardial cAMP (Fig. 6 ) that was smaller than the increase in the cyclic nucleotide caused by 1 ^M isoproterenol. hi contrast to the increase in cGMP caused by 10 minutes of ischemia, cAMP was not influenced by the ischemic conditions. Perhaps in the ischemic heart both the fall in myocardial ATP concentration (substrate for cAMP formation) and an augmentation of cAMP phosphodiesterase activity caused by an elevated concentration of cGMP (Beavo et al., 1971) do not permit cAMP to increase significantly. Previously, ischemia has been shown to increase cAMP in the heart (Wollenberger et al., 1969; Dobson and Mayer 1973) . However, the hearts were intact and catecholamine release probably was an important factor in the augmentation of myocardial cAMP.
The removal of Ca 2+ from the PSS for 1 minute partially inhibited the ischemia-induced increase in cGMP but did not prevent the acetylcholine-induced increase in the cyclic nucleotide (Fig. 8) . Twenty minutes of Ca 2+ -free perfusion was required to prevent the increase in cGMP caused by acetylcholine. Since the hearts perfused with Ca 2+ -firee PSS ceased contracting within 15 seconds, the Ca 2+ involved in excitation-contraction coupling probably does not play a direct role in the elevation of cardiac cGMP caused by acetylcholine. In the present studies the requirement of Ca 2+ for the acetylcholine-stimulated increase in cyclic GMP agrees with the studies of Schultz et al. (1973) . These investigators reported that acetylcholine failed to increase the cGMP of rat ductus deferens when the preparation was incubated in the absence of Ca 2+ for 30 minutes. The role of Ca 2+ in the ischemiainduced elevation of myocardial cGMP may involve the formation and or disappearance of some metabolites(s) but awaits further investigation.
In summary, the results indicate that (1) the acetylcholine-produced increase in cGMP is not necessarily associated with a decrease in contractility-whether or not there is a correlation depends on the techniques and heart preparation employed;
(2) ischemia but not anoxia increases myocardial cGMP; (3) the acetylcholine-induced increase in cGMP is blocked by atropine and does not depend directly on the presence of external Ca 2 " 1 "; (4) the ischemia-elicited increase in cardiac cGMP is not prevented by atropine, but is largely dependent on external Ca 2+ .
